Clinical Trial Update: Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing sirolimus with cyclosporine in a calcineurin inhibitor-free regimen for kidney transplant recipients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant

Drugs mentioned

• CYCLOSPORINE (cyclosporine)
• Rapamune (sirolimus)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Kidney Transplant | Phase 3 | Status: TERMINATED